wild/inflammation

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to herbal compositions and methods for combating inflammation. 2. Description of the Prior Art Arthritic disorders, including rheumatism, osteoarthritis, dysplasia, lupus, bursitis, and gout, are all

TECHNICAL FIELD This invention relates to molecular and cellular biology, biochemistry, molecular genetics, gene therapy, and drug design and discovery. In one aspect, the invention is directed to genetically altered fish of the family Cyprinidae, or genus Danio, including zebrafish (Danio rerio)

RELATED APPLICATIONS This application is the U.S. National Phase under 35 U.S.C. 371 of International Application PCT/DE02/00003, filed May 8, 2002, which was published in a language other than English and which claims priority of Germany 101 00 238.6, filed Jan. 5, 2001. The invention relates to a

FIELD OF THE INVENTION The present invention relates to glucagon-like-peptide-2 (GLP-2) analogues and their medical use, for example in the prophylaxis or treatment of stomach and bowel-related disorders and for ameliorating side effects of chemotherapy and radiation therapy. BACKGROUND OF THE

The present invention provides RANTES mutants with reduced pro-inflammatory activity, increased HIV-suppressive activity, and antagonistic activity to wild-type chemokines. Chemokines are small proteins involved in inflammatory mechanisms and in physiologic circulation of hemopoietic cells. Several

SEQUENCE LISTING The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 11, 2015, is named 37151-706.601_SL.txt and is 113,105 bytes in size. BACKGROUND OF

The present invention provides RANTES mutants with reduced pro-inflammatory activity, increased HIV-suppressive activity, and antagonistic activity to wild-type chemokines. Chemokines are small proteins involved in inflammatory mechanisms and in physiologic circulation of hemopoietic cells. Several

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention in the field of medicine and immunology, particularly innate immunity, relates to prevention and treatment of influenza infections with granulocyte-macrophage colony stimulating factor (GM-CSF) and to the prevention and treatment of

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention relates generally to compositions and methods involved in the therapeutic use of protein C. Specifically, the invention is directed to a novel protein C that is activated by free thrombin at an increased rate, and upon activation,

This invention relates to mutants of human RANTES (hRANTES) which, relative to the wild-type molecule, have a reduced tendency to aggregate into large multimeric complexes at physiological ionic strength and pH, and are less pro-inflammatory. This invention also relates to the use of such mutants in

FIELD OF THE INVENTION The present invention relates to novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and to their use for therapeutic treatment of

BACKGROUND OF THE INVENTION Asthma and rhinitis are atopic (allergic) diseases affecting between 20-30% of the population. They are associated with acute and chronic inflammatory responses resulting from contact with protein particles in the environment. Initially, exposure of the airway immune

FIELD OF THE INVENTION The present invention relates, generally, to molecular biology and biochemistry and, more specifically, to products of the IKK.gamma. gene and to methods for making and using such products. BACKGROUND OF THE INVENTION Nuclear factor .kappa.B ("NF-.kappa.B") is a family of

TECHNICAL FIELD This invention relates to a mutant form of interleukin 10 (IL-10) lacking some of the functions of wild-type IL-10, and compositions and methods for use thereof. BACKGROUND Interleukin-10 (IL-10), also known as cytokine synthesis inhibitory factor (CSIF), is normally expressed in T

2. FIELD OF THE INVENTION The present invention relates to methods of treating or preventing cancer and other diseases using molecules, particularly polypeptides, more particularly immunoglobulins (e.g., antibodies), comprising a variant Fc region, wherein said variant Fc region comprises at least